Across TCGA pan-cancer cohorts, SAXO2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SAXO2 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SAXO2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SAXO2 expression acts as an unfavorable survival marker.

CESC, BLCA, and PRAD are the cancer types where SAXO2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.203	0.759	.021	6	view →
BLCA	OS	Median	All	0.166	0.616	.043	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SAXO2 tumor-vs-normal RNA expression · all SAXO2 data types